Herzum Astrid, Burlando Martina, Molle Mattia F, Micalizzi Claudia, Cozzani Emanuele, Parodi Aurora
Department of Dermatology Di.S.Sal San Martino Polyclinic Hospital IRCCS University of Genoa Genoa Italy.
Clin Case Rep. 2021 Dec 7;9(12):e05092. doi: 10.1002/ccr3.5092. eCollection 2021 Dec.
We report the third case of cutaneous lichen planus (LP) following COVID-19 BNT162b2 vaccination in a 59-year-old woman with previous LP. The reactivation of LP in patients with dormant LP suggests a possible vaccine-induced immune dysregulation. We suggest that the already described vaccine-induced upregulation of Th1 response may play a relevant role in LP reactivation, through an increase in inflammatory cytokines involved in the pathogenesis of LP. Interestingly, LP has already been associated with vaccinations and viral infections including COVID-19 disease. However, the exact mechanism underlying LP (re)activation after Pfizer-BiotNtech COVID-19 vaccination is still widely unknown and needs to be further investigated.
我们报告了第三例在接种新冠病毒BNT162b2疫苗后出现皮肤扁平苔藓（LP）的病例，患者为一名59岁有既往LP病史的女性。潜伏性LP患者中LP的重新激活提示可能存在疫苗诱导的免疫失调。我们认为，已报道的疫苗诱导的Th1反应上调可能通过增加参与LP发病机制的炎性细胞因子，在LP重新激活中发挥相关作用。有趣的是，LP已与包括新冠病毒疾病在内的疫苗接种和病毒感染相关联。然而，辉瑞-生物科技公司新冠病毒疫苗接种后LP（再）激活的确切机制仍广泛未知，需要进一步研究。
Zotero 插件